NCT06888232

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients: A Single Center Experience From South Punjab, Pakistan

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Muhammad Aamir Latif · Academic / Other
• Sex: All
• Age: 2 Years – 5 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.

Detailed description

Given the significant burden of transfusion dependency, an effective and safe inducer is needed that could improve quality of life and reduce the healthcare costs associated with frequent transfusions and iron chelation therapy. If this study could establish the safety of thalidomide in terms of teratogenicity along with its efficacy, it would be a great support to multi-transfused thalassemic children.

Conditions

• Thalassemia

Interventions

Type	Name	Description
DRUG	Thalidomide	Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2025-03-21
• Last updated: 2025-03-21

Locations

1 site across 1 country: Pakistan